Physician profile
Jonathan Rhodes
NPI 1477062800
$1,661.54
in general payments reported to CMS, 2019-2025
17 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.85 · 2022: $369 · 2023: $575 · 2024: $132 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.89 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.71 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.81 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $146.71 | 2023 | Invega Sustenna, Spravato, Invega Trinza |
| Novartis Pharmaceuticals Corporation | $106.11 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $93.18 | 2022-2024 | Uzedy |
| Indivior INC. | $93.11 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $55.74 | 2025 | Cobenfy |
| Alkermes, INC. | $52.70 | 2023 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $52.37 | 2022-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $52.24 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.64 | 2021-2022 | |
| Cvrx, INC. | $17.19 | 2024 | Barostim Neo System |
| Vanda Pharmaceuticals INC. | $17.06 | 2025 | Fanapt |
| Noven Therapeutics, LLC | $14.63 | 2022 | |
| Axsome Therapeutics, INC. | $14.10 | 2024 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.01 | 2021 | |
| Amgen INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.